N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase

a technology of indoleamine and hydroxyamidinoheterocycles, which is applied in the direction of biocide, drug composition, immunological disorders, etc., can solve the problems of quinolinic acid (quin), kynurenine metabolites such as 3-hydroxy-kynurenine, and inability of fetus to fully explain the survival of fetal allografts

Inactive Publication Date: 2008-05-29
INCYTE
View PDF23 Cites 38 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Anatomic separation of mother and fetus and antigenic immaturity of the fetus cannot fully explain fetal allograft survival.
Furtherm

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
  • N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
  • N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase

Examples

Experimental program
Comparison scheme
Effect test

example 1

N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-5-[2-(methylamino)-1,3-thiazol-4-yl]isoxazole-3-carboximidamide

[0197]

Step A: Ethyl-3-[2-(methylamino)-1,3-thiazol-4-yl]isoxazole-3-carboxylate

[0198]

[0199]A solution of ethyl 3-(bromoacetyl)isoxazole-3-carboxylate (100 mg, 0.40 mmol) and methylthiourea (69 mg, 0.76 mmol) in acetic acid (3.0 mL) was heated at 150° C. in the microwave for 15 minutes. Solvent was removed in vacuo to give the crude which was used without purification. MF=C10H11N3O3S; LCMS calculated for C10H11N3O3S (M+H)+: m / z=254.

Step B: 3-[2-(Methylamino)-1,3-thiazol-4-yl]isoxazole-3-carboxylic acid

[0200]

[0201]A solution of ethyl-3-[2-(methylamino)-1,3-thiazol-4-yl]isoxazole-3-carboxylate (65 mg, 0.26 mmol) in ethanol (3.0 mL) was treated with 1N aqueous sodium hydroxide (0.30 mL, 0.28 mmol) and the mixture was stirred at room temperature for 2 h. The mixture was neutralized with 1 N aqueous hydrochloric acid and concentrated in vacuo to give the crude which was used without purif...

example a

Human idoleamine 2,3-dioxygenasae (IDO) Enzyme Assay

[0211]Human idoleamine 2,3-dioxygenase (IDO) with an N-terminal His tag was expressed in E. coli and purified to homogeneity. IDO catalyzes the oxidative cleavage of the pyrrole ring of the indole nucleus of tryptophan to yield N′-formylkynurenine. The assays were performed at room temperature as described in the literature using 95 nM IDO and 2 mM D-Trp in the presence of 20 mM ascorbate, 5 μM methylene blue and 0.2 mg / mL catalase in 50 mM potassium phosphate buffer (pH 6.5). The initial reaction rates were recorded by continuously following the absorbance increase at 321 nm due to the formation of N′-formlylkynurenine. See: Sono, M., Taniguchi, T., Watanabe, Y., and Hayaishi, O. (1980) J. Biol. Chem. 255, 1339-1345. Compounds of the invention were found to be inhibitors of IDO according to this assay. Data is provided below in Table 2. The symbol “+” indicates IC5050≦10,000 μM. The symbol “+++” indicates IC50>10,000 μM.

TABLE 2Ex....

example b

Determination of Inhibitor Activity in HeLa Cell-Based Indoleamine 2,3-dioxygenase (IDO) / Kynurenine Assay

[0212]HeLa cells (#CCL-2) were obtained from the American Type Tissue Culture Collection (ATCC, Manassas, Va.) and routinely maintained in minimum essential medium (eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g / L sodium bicarbonate, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 10% fetal bovine serum (all from Invitrogen). Cells were kept at 37° C. in a humidified incubator supplied with 5% CO2. The assay was performed as follows: HeLa cells were seeded in a 96 well culture plate at a density of 5×103 per well and grown overnight. On the next day, IFN-γ (50 ng / mL final concentration) and serial dilutions of compounds (in total volume of 200 μL culture medium) were added into cells. After 48 hours of incubation, 140 μL of the supernatant per well was transferred to a new 96 well plate. 10 μL of 6.1 N trichloroacetic acid (#T0699, Sigma) was mi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Electrical conductanceaaaaaaaaaa
Electrical conductanceaaaaaaaaaa
Electrical conductanceaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Ser. No. 60 / 845,700, filed Sep. 19, 2006, the disclosure of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.BACKGROUND OF THE INVENTION[0003]Tryptophan (Trp) is an essential amino acid required for the biosynthesis of proteins, niacin and the neurotransmitter 5-hydroxytryptamine (serotonin). The enzyme indoleamine 2,3-dioxygenase (also known as INDO or IDO) catalyzes the first and rate limiting step in the degradation of L-tryptophan to N-formyl-kynurenine. In human cells, a depletion of Trp resulting from IDO activity is a prominent gamma interferon (IFN-γ)-inducible antimicrobial effector mechanism. IFN-γ stimulation induces activation of IDO, which leads to a depletion of Trp, thereby arresting the growth of Trp-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/426A61P35/00C07D261/06A61K31/41C07D249/04A61K31/42C07D277/20
CPCC07D261/18C07D261/20C07D417/04C07D413/04C07D277/56A61P11/06A61P17/02A61P25/00A61P25/24A61P25/28A61P27/12A61P31/12A61P31/18A61P35/00A61P35/02A61P37/00A61P37/06A61P43/00
Inventor COMBS, ANDREW P.GLASS, BRIAN M.SPARKS, RICHARD B.YUE, EDDY WAI TSUN
Owner INCYTE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products